Zydus Lifesciences gains on getting USFDA`s approval for Lidocaine and Prilocaine cream
Zydus Lifesciences is currently trading at Rs. 987.20, up by 8.10 points or 0.83% from its previous closing of Rs. 979.10 on the BSE.
The scrip opened at Rs. 969.00 and has touched a high and low of Rs. 988.70 and Rs. 965.90 respectively. So far 14140 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 648.05 on 21-Dec-2023.
Last one week high and low of the scrip stood at Rs. 991.80 and Rs. 955.40 respectively. The current market cap of the company is Rs. 99254.92 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.17% and 6.85% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Lidocaine and Prilocaine Cream USP, 2.5%/2.5% (USRLD: EMLA Cream, 2.5%/2.5%). Lidocaine and Prilocaine Cream USP is indicated as a topical anaesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anaesthesia.
Lidocaine and Prilocaine cream will be produced at the Group’s topical manufacturing site at Changodar, Ahmedabad. Lidocaine and Prilocaine cream had annual sales of $22.05 million in the United States (IQVIA MAT October 2024). The group now has 412 approvals and has so far filed over 473 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
